Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior ChemotherapyGeorge D. Demetri, Jean‐Yves Blay, Nicolas Penel et al.|Journal of Clinical Oncology|2013Cited by 243
A Phase I Trial of Oral Ridaforolimus (AP23573; MK-8669) in Combination with Bevacizumab for Patients with Advanced CancersJohn Nemunaitis, Monica Mita, Howard S. Höchster et al.|Clinical Oncology|2013Cited by 13
Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.Jean‐Yves Blay, George D. Demetri, Sant P. Chawla et al.|Journal of Clinical Oncology|2012Cited by 11